Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
33 hedge funds and large institutions have $37.5M invested in Sorrento Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 6 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
11% less funds holding
Funds holding: 37 → 33 (-4)
27% less capital invested
Capital invested by funds: $51.5M → $37.5M (-$14.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.72M |
| 2 |
B
Baird
Milwaukee,
Wisconsin
|
+$703K |
| 3 |
TC
Talkot Capital
Sausalito,
California
|
+$581K |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
+$353K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.17M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
-$878K |
| 3 |
RFS
Rockefeller Financial Services
New York
|
-$341K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$136K |
| 5 |
Jane Street
New York
|
-$128K |
SRNE Hedge Fund Activity: Q3 2014 in Review
33 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2014, worth a combined $37.5M — down 27% from $51.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SRNE and 2 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.72M. The largest seller was Fidelity Investments, cutting an estimated $1.17M.
- 33 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2014, down from 37 in Q2 2014.
- Funds reported $37.5M of Sorrento Therapeutics, Inc. stock for Q3 2014, down 27% quarter-over-quarter.
- 2 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2014 and 6 closed out, a net change of -4 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2014 was JP Morgan Chase, an estimated $1.72M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $1.17M sold.
Based on aggregated 13F filings for Q3 2014.